Audfly Focusound Screen®: Transforming Audio Delivery in Consumer and Commercial Sectors
EINPresswire.com / -- Audfly Technology, a company specializing in ultrasonic directional sound, has recently unveiled its latest development in Focusound Screen ® technology. This innovation aims to enhance the way audio is delivered by integrating sound transmission capabilities into display screens.
Audfly's Focusound Screen® is a transparent film-based solution designed to be seamlessly incorporated into screens, effectively turning them into directional speakers. The technology is intended to deliver sound directly to the user, thereby enhancing privacy and improving communication clarity. Compared to traditional speakers that emit sound in multiple directions, Focusound Screen® is engineered to direct sound more precisely to the intended listener, potentially reducing external noise pollution.
Focusound Screen® is expected to find applications in both consumer and commercial sectors. In personal computing, it may enhance media consumption, gaming, and virtual meetings by providing clear, private sound without the need for external speakers or headphones. For handheld gaming devices, it could offer an immersive experience while minimizing disturbance to others.
Beyond consumer use, Focusound Screen® is poised to impact commercial environments. In retail and hospitality settings, it could enable targeted audio messaging, allowing stores to provide product information with less background noise interference. Digital signage and interactive kiosks may also benefit from the technology for clearer and more engaging customer interactions. Additionally, corporate and educational settings could leverage the precise sound delivery in conference rooms, training centers, and public information systems to ensure that messages reach the intended audience with minimal audio spillover.
Audfly has reportedly integrated this technology into select smart devices, such as the Lenovo ThinkCentre M90a Pro Gen 6, which is noted as the world's first all-in-one PC equipped with Focusound Screen®. This integration highlights the growing interest in directional sound technology as a potential component in the future of smart audio solutions.
'With the increasing demand for personalized and private audio experiences, directional sound technology is anticipated to play a significant role in shaping how we interact with digital content,' commented Gu, an audio technology specialist. 'Audfly's Focusound Screen® represents an important development in advancing sound delivery to be more intelligent, efficient, and user-centric.'
Audfly recently showcased its latest generation of Focusound Screen® technology at CES 2025, attracting interest from industry leaders, manufacturers, and consumers. As adoption of the technology grows across various sectors, it is expected to influence the standards for audio integration in smart devices and commercial applications.
X
LinkedIn
Instagram
YouTube
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
United States Presidential Culinary Museum® Celebrates America 250 with Launch of "The Washington's Famous Syllabub Drink"
GROVER, N.C., June 11, 2025 /PRNewswire/ -- In honor of the Semiquincentennial—America's 250th anniversary of independence—the United States Presidential Culinary Museum® is continuing to promote the national celebration with a unique culinary tribute: the Founding Families Syllabub, a fun, free-wheeling drink of the beloved Colonial-era libations. America's 250th anniversary is officially being marked by a year‑long series of national events, beginning Memorial Day 2025 and rocketing into July 4, 2026. With events spanning the federal government, local institutions, nonprofits, and the public, this multi-faceted celebration is meant to rekindle our country's rich history and spirit. Syllabub, a frothy, sweet drink traditionally made with cream, sugar, and wine or brandy, has a storied past dating back to the 1500s during the reign of the Tudors starting with King Henry VII, son of Edmund Tudor, 1st Earl of Richmond, and Lady Margaret Beaufort. It remained a favorite for more than 300 years. Long before eggnog with a dash of cinnamon became the seasonal staple, Syllabub was enjoyed year-round—both in England and in the American colonies. The drink's popularity grew immensely in the 1700s, despite sugar being heavily taxed and politically controversial for British colonists. In America, even amidst this taxation tension, Syllabub became a fashionable indulgence. By the time of the American Revolution, it had become a signature at social gatherings, particularly among Founding Fathers and First Lady Dolley Madison, who famously served it at White House receptions. Syllabub wasn't just a drink—it was an experience. It had its own glassware, utensils, and preparation techniques designed to create the perfect whipped froth on top. Initially served in clay mugs, its visual appeal led to the development of clear glass vessels, which triggered a consumer revolution of insanity purchasing. Middle-class households began purchasing specialty Syllabub sets, and merchants advertised entire fancy collections in their shops. During the Revolutionary War, the drink remained popular—even when fancy glassware was hard to come by. Colonists, considering themselves British Americans, were keen to keep pace with fashion trends from the U.K.—from food and drink to décor and dress. Owning Syllabub glassware was as much about identity as it was about indulgence. Today, the United States Presidential Culinary Museum® is proud to revive this historic beverage with an authentic, verified recipe from George and Martha Washington. Syllabub was famously served at the W Mount Vernon estate, Jefferson's Monticello, the Madison's Montpelier, according to historical records and is featured there today as well as at Williamsburg, The American Revolutionary War Living History Center, and Old Salem Village. Event Highlights: - Launch reception on July 4, 2025, at 3:00 PM in the Museum's Presidential Dining Room - Syllabub tasting stations, menu pairings, and live culinary demonstrations including non-alcoholic versions and how to create those - Historical talk series, "Sips from the Past: Colonial Drinks & Diplomacy" streamed on the PRESENTS™ Network via YouTube, Linkedin LIVE, Instagram, TWITCH, and Facebook Former White House Master Chef Marti Mongiello with his wife, Executive Chef Stormy Mongiello, Museum President, and Tournant Chef Barry Mongiello note: "Food—and drink—tell stories. Our syllabub bridges gastronomy and history, letting people taste, touch, and smell the touch of Colonial America. We're proud to be part of the nation's 250th celebrations." About the United States Presidential Culinary Museum® Located in Grover, NC., the town celebrates being named after President Grover Cleveland and is in Cleveland County, NC. It's dedicated to preserving and sharing the culinary traditions of America's presidents, first ladies, and their families. Through exhibitions, TV appearances, keynote speeches, White House replica luncheons and dinners, recipes, and tastings, it explores how food and drink reflect cultural and historical moments. Marti and Stormy Mongiello serve as the leading chefs, and both are disabled veterans of 36 years combined military service. Media Contact:Master Chef Marti Mongiello, MBA, MA, MCFEThe United States Presidential Culinary Museum® The US Presidential Service Center®301 Cleveland Ave, Grover, NC 28073 and (704) 937-2940ceo@ Historic Recipe: Washington Family Syllabub From the Kitchen of President George and Martha Washington. Perfected by Executive Chef to the Washington's, Hercules Posey – who later ran away from being a slave. Ingredients:- 1 Quart of heavy cream - 1 Cup of white wine- 6 Tablespoons white sugar - 1 whole nutmeg (grated) or ground nutmeg- 2 Tablespoons of rose water (can be bought or made with hot water and rose petals)- Zest of 1/2 lemon- Sprig of Rosemary- Salt (a pinch) Instructions from the manuscripts given by Franics Parke Custis to Martha Washington: Scald the cream together with the nutmeg, cut in quarters. Remove from the fire and when cool, pour in a glass jar. Let stand overnight. Mix the white wine, rose water, sugar, and a pinch of salt. Pour the cream over this and lay in the rosemary and lemon peel. Let stand for five or six hours until the curds form. The modern method: Pour cream into a bowl and beat with a whisk or electric mixer until soft peaks appear. Add the sugar, lemon zest, salt, rose water, nutmeg and beat briefly. Pour in the wine (experiment with sweet or dry wines, etc.) and mix then put into glasses and place into the refrigerator overnight to separate into cool layers. Decorate with more lemon zest and the sprigs of Rosemary. All types of other decorations can be fantasized about and made as well as adding even more whipped cream on top with grated nutmeg. Traditionally served in Syllabub glasses to show off the distinct layers, this recipe was a favorite of all of the revolutionary founding families and frequently offered at elegant affairs at the White House, private first family estates, on Presidential yachts and rail cars, and at the Camp David Resort and Conference Center. A "Whipt Syllabub" of the era would include many different flavor ideas of lemon and strawberry and other ideas and also could be made with egg whites and heavy cream mixed with sugar and wine beaten to a froth. View original content to download multimedia: SOURCE The US Presidential Culinary Museum Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of the 13 Biotech Stocks with Huge Upside Potential. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of the stocks with the biggest upside. It presented late-breaking Phase 4 data on Xywav® at SLEEP 2025, which included findings from the XYLO and DUET trials. A biopharmaceutical scientist in their lab, studying a newly-diagnosed therapy-related acute myeloid leukemia. . In the XYLO study (n=43), moving from high-sodium to low-sodium oxybate resulted in a substantial decrease in 24-hour ambulatory systolic blood pressure (−4.1 mmHg; P=0.0019). SBP reduction during the day (−5.1 mmHg; P=0.0003) and while seated (−9.2 mmHg; P<0.0001) were secondary objectives. The TEAEs were moderate or mild. DUET data from 24 subjects taking 9-12g Xywav nightly displayed improvement in excessive daytime sleepiness and narcolepsy severity with an average dose of 11.2g during the stable period. Xywav is the sole FDA-approved low-sodium oxybate for cataplexy or EDS in narcolepsy and idiopathic hypersomnia. Xywav reduces nightly sodium intake by up to 92% compared to Xyrem®, lowering cardiovascular risk, which is a serious issue in narcolepsy patients. Both indications were awarded Orphan Drug Exclusivity by the FDA. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)'s data underscores how crucial it is to lower sodium intake in long-term sleep disorder treatment plans. While we acknowledge the potential of JAZZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected later this month NEWARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT), today reported its financial results for the third quarter and first nine months of fiscal year 2025 ended April 30, 2025. 'We are pleased to have completed our merger with Cyclo Therapeutics and look forward to reporting the topline data from the 48-week interim analysis of the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 anticipated later this month,' said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings. Mr. Jonas added, 'We have enhanced our financial position with the closing of a $25 million rights offering earlier this month which will support advancing this potential new treatment option for patients suffering from this rare genetic disease.' Rafael Holdings, Inc. Third Quarter Fiscal Year 2025 Financial Results As of April 30, 2025, we had cash and cash equivalents of $37.9 million. On June 4, 2025, the Company announced the closing of a $25 million rights offering, which, including the funding of the backstop commitment by the Jonas family, raised net proceeds of $24.9 million after deduction of certain expenses incurred in connection with the offering. For the three months ended April 30, 2025, we recorded a net loss attributable to Rafael Holdings of $4.8 million, or $0.19 per share, versus a net loss of $32.4 million, or $1.36 per share in the year ago period. The year over year decrease in net loss is attributable to non-cash items, primarily unrealized losses of $1.4 million on the Company's investment in Cyclo equity which we purchased in advance of the potential merger in the current period versus $4.4 million in the year ago period, combined with an in-process R&D expense of $89.9 million related to the acquisition of Cornerstone, partially offset by a $31.3 million recovery of receivables from Cornerstone in the year ago period. Research and development expenses were $3.0 million for the three months ended April 30, 2025, compared to $1.5 million in the year ago period. The year over year increase relates to the inclusion in the current year period of spending at Cyclo Therapeutics following the March 25, 2025 merger and the activity of Cornerstone and Day Three which were consolidated with Rafael Holdings during fiscal 2024. General and administrative expenses were $3.2 million for the three months ended April 30, 2025, compared to $1.9 million in the year ago period. The year over year increase relates to the inclusion of Cyclo Therapeutics following closing of the merger, and the activity of Cornerstone and Day Three, following their consolidation. Rafael Holdings, Inc. First Nine Months Fiscal Year 2025 Financial Results For the nine months ended April 30, 2025, we recorded a net loss attributable to Rafael Holdings of $18.4 million, or $0.73 per share, versus a net loss of $29.9 million, or $1.26 per share in the year ago period. The year over year decrease in net loss is attributable to in-process R&D expense of $89.9 million related to the acquisition of Cornerstone net with a $31.3 million recovery of receivables from Cornerstone in the year ago period and $3.2 million in unrealized gains on the Company's investment in Cyclo equity. Research and development expenses were $5.3 million for the nine months ended April 30, 2025, compared to $2.6 million in the year ago period. The year over year increase relates to the merger with Cyclo Therapeutics which closed on March 25, 2025, and the activity of Cornerstone and Day Three, which were consolidated with Rafael Holdings during fiscal 2024. For the nine months ended April 30, 2025, general and administrative expenses were $8.3 million compared to $6.5 million in the same period in the prior year. The year over year increase relates to the merger with Cyclo Therapeutics which closed on March 25, 2025, and the activity of Cornerstone and Day Three, which were consolidated with Rafael Holdings during fiscal 2024. About Rafael Holdings, Inc. Rafael Holdings, Inc. holds interests in clinical and early-stage pharmaceutical and certain other companies, including our wholly owned subsidiary, Cyclo Therapeutics, LLC, a clinical stage biotechnology company dedicated to developing Rafael's lead clinical candidate, Trappsol® Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 ('NPC1'), a rare, fatal, and progressive genetic disorder. Rafael also holds majority equity interests in LipoMedix Pharmaceuticals Ltd., a clinical stage pharmaceutical company, Cornerstone Pharmaceuticals, Inc., formerly known as Rafael Pharmaceuticals Inc., a cancer metabolism-based therapeutics company, Rafael Medical Devices, LLC, an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and Day Three Labs, Inc., a company which empowers third-party manufacturers to reimagine their existing cannabis offerings. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans regarding the further evaluation of clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those disclosed under the caption 'Risk Factors' in our Annual Report on Form 10-K for the year ended July 31, 2024, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Contact:Barbara 274-2825 RAFAEL HOLDINGS, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) April 30, 2025 July 31, 2024 (audited) ASSETS CURRENT ASSETS Cash and cash equivalents $ 37,936 $ 2,675 Available-for-sale securities — 63,265 Interest receivable — 515 Prepaid clinical trial costs 2,968 — Convertible note receivables, due from Cyclo — 5,191 Accounts receivable, net of allowance for credit losses of $245 at April 30, 2025 and July 31, 2024 414 426 Inventory 288 — Prepaid expenses and other current assets 837 430 Total current assets 42,443 72,502 Property and equipment, net 1,614 2,120 Non-current prepaid clinical trial costs 1,399 — Investments – Cyclo — 12,010 Investments - Hedge Funds — 2,547 Convertible note receivable classified as available-for-sale 1,719 1,146 Goodwill 28,278 3,050 Intangible assets, net 1,027 1,847 In-process research and development 31,575 1,575 Other assets 41 35 TOTAL ASSETS $ 108,096 $ 96,832 LIABILITIES AND EQUITY CURRENT LIABILITIES Accounts payable $ 7,793 $ 2,556 Accrued expenses 1,866 1,798 Convertible notes payable 614 614 Other current liabilities 93 113 Due to related parties 664 733 Installment note payable — 1,700 Total current liabilities 11,030 7,514 Accrued expenses, noncurrent 3,445 2,982 Convertible notes payable, noncurrent 76 73 Other liabilities 25 5 Deferred income tax liability 9,002 — TOTAL LIABILITIES 23,578 10,574 COMMITMENTS AND CONTINGENCIES EQUITY Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of April 30, 2025 and July 31, 2024 8 8 Class B common stock, $0.01 par value; 200,000,000 shares authorized, 31,240,188 issued and outstanding (excluding treasury shares of 101,487) as of April 30, 2025, and 24,142,535 issued and 23,819,948 outstanding (excluding treasury shares of 101,487) as of July 31, 2024 312 238 Additional paid-in capital 296,648 280,048 Accumulated deficit (220,169 ) (201,743 ) Treasury stock, at cost; 101,487 Class B shares as of October 31, 2024 and July 31, 2024 (168 ) (168 ) Accumulated other comprehensive income related to unrealized income on available-for-sale securities 219 111 Accumulated other comprehensive income related to foreign currency translation adjustment 3,728 3,691 Total equity attributable to Rafael Holdings, Inc. 80,578 82,185 Noncontrolling interests 3,940 4,073 TOTAL EQUITY 84,518 86,258 TOTAL LIABILITIES AND EQUITY $ 108,096 $ 96,832 RAFAEL HOLDINGS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited, in thousands, except share and per share data) Three Months Ended April 30, Nine Months Ended April 30, 2025 2024 2025 2024 Revenues $ 362 $ 336 $ 567 $ 472 Cost of Infusion Technology revenue 31 85 106 85 Cost of product revenue 9 — 9 — SG&A Expenses 3,170 1,923 8,284 6,524 R&D Expenses 3,003 1,526 5,276 2,627 In-process R&D expense — 89,861 — 89,861 Depreciation and amortization 62 102 238 157 Loss on impairment of goodwill — — 3,050 — Operating Loss (5,913 ) (93,161 ) (16,396 ) (98,782 ) Interest income 472 502 1,529 1,777 Loss on initial investment in Day Three upon acquisition — — — (1,633 ) Realized gain on available-for-sale securities — 945 178 1,521 Realized loss on investment in equity securities — — — (46 ) Realized gain on investment - Cyclo — — — 424 Unrealized (loss) gain on investments - Cyclo (1,393 ) (4,395 ) (5,144 ) 3,199 Unrealized gain (loss) on convertible notes receivable, due from Cyclo 383 — (719 ) — Unrealized loss on investments - Hedge Funds — (3 ) — (118 ) Recovery of receivables from Cornerstone — 31,305 — 31,305 Interest expense (165 ) (85 ) (490 ) (85 ) Other income, net 154 — 74 118 Loss before Incomes Taxes (6,462 ) (64,892 ) (20,968 ) (62,320 ) Benefit from income taxes 2,411 2,599 2,379 2,593 Equity in loss of Day Three — — — (422 ) Consolidated net loss (4,051 ) (62,293 ) (18,589 ) (60,149 ) Net income (loss) attributable to noncontrolling interests 728 (29,942 ) (163 ) (30,207 ) Net loss attributable to Rafael Holdings, Inc. $ (4,779 ) $ (32,351 ) $ (18,426 ) $ (29,942 ) Loss per share Basic and diluted (0.19 ) (1.36 ) (0.73 ) (1.26 ) Loss per basic common share $ (0.19 ) $ (1.36 ) $ (0.73 ) $ (1.26 ) Weighted average shares in calculation 25,238,501 23,777,493 23,131,655 23,687,781 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
